Aligos Therapeutics, Inc. ALGS has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201.
Lawrence Blatt, CEO and Chairman, said: This is an important next step in our evaluation of ALG-000184 as a chronic suppressive therapy and/or part of a functional cure regimen in patients with CHB. With the initiation of this 12-week cohort at the 100 mg dose level, we can now explore whether longer-term dosing continues to be well tolerated and if greater suppression of important viral parameters, including HBV DNA and RNA, in HBeAg-positive subjects can be achieved.”
Aligos indicated the oral ALG-000184 doses up to 100 mg given daily for 28 days were well tolerated with excellent pharmacokinetic properties and potentially best-in-class antiviral activity in both HBeAg-negative and -positive CHB subjects.
The company plans to share data readout from this cohort at a scientific conference in the fourth quarter of 2022.
Price Action : Aligos shares are trading around 4 percent down at $1.38 on Monday at the time of publication.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.